Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) traded down 7% on Tuesday. The stock traded as low as $15.03 and last traded at $15.2310. Approximately 2,052 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 26,654 shares. The stock had previously closed at $16.37.
Analyst Ratings Changes
JSPR has been the subject of a number of analyst reports. Piper Sandler began coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $60.00 price objective for the company. William Blair assumed coverage on shares of Jasper Therapeutics in a research note on Wednesday, October 14th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Jasper Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $220.00.
Get Our Latest Stock Analysis on Jasper Therapeutics
Jasper Therapeutics Trading Down 9.1%
The business has a fifty day moving average of $17.34 and a 200-day moving average of $24.81. The company has a market cap of $495.24 million, a PE ratio of -0.31 and a beta of 3.30.
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($3.00) earnings per share for the quarter, topping the consensus estimate of ($8.03) by $5.03. As a group, research analysts predict that Jasper Therapeutics, Inc. will post -28.23 EPS for the current year.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation. Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.
See Also
- Five stocks we like better than Jasper Therapeutics
- Fox’s $22 Billion Roku Acquisition Reshapes Its Streaming Business
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
